Insmed’s Brinsupri Exceeds Sales Expectations for Bronchiectasis Treatment
Insmed reported that Brinsupri generated $144.6 million in sales in the first full quarter of 2025, surpassing expectations for the treatment of bronchiectasis. This strong initial commercial performance highlights continued demand for innovative therapies in chronic lung conditions.
Insmed's Brinsupri Sales Surpass Expectations
- Brinsupri, a recently approved drug for bronchiectasis, posted $144.6 million in sales in its full quarter of 2025.
- The sales figure exceeded initial projections, indicating robust market acceptance.
- Bronchiectasis is a chronic lung condition with significant unmet medical needs, underscoring the importance of new therapeutic options.
Market Implications
- The drug's blowout sales performance may enhance Insmed's position in pulmonary therapeutics.
- Positive early sales can drive further research and potential expansion in related indications.
Source: BioSpace
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.